Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy
SGO 2021 Virtual Annual Meeting on Womens Cancer
Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated, platinum-resistant, or platinum-sensitive relapsed ovarian cancer (ID #10191).
The ASCO Post Staff
Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients undergoing surgery for ovarian cancer. Over the 12-year study period, mortality decreased for all women with ovarian cancer, despite a concurrent increase in frail patients (ID #10209).
The ASCO Post Staff
Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have progressed on prior systemic therapy (ID # 10224).
The ASCO Post Staff
Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose tumors express PD-L1.
The ASCO Post Staff
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, discusses results from the ORZORA trial, which showed the efficacy of olaparib in patients with platinum-sensitive relapsed ovarian cancer is similar, whether they have a germline or somatic BRCA mutation. This information could prove useful for clinical practice (ID #10226).
The ASCO Post Staff
William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Almost half of the patients treated with olaparib in the study were disease-free at 5 years, vs 20% of those treated with placebo (ID# 10224).
